CFI-402411 is under clinical development by Treadwell Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CFI-402411’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CFI-402411 overview
CFI-402411 is under development for the treatment of solid tumors including non-small cell lung cancer, small-cell lung cancer, cutaneous melanoma, merkel cell carcinoma, head and neck squamous cell carcinoma, anal cancer, urothelial cancer, clear cell or non-clear cell renal cell carcinoma, triple negative breast cancer, pancreatic cancer, prostate cancer, colorectal cancer, endometrial cancer, cervical cancer, gastroesophageal cancer, hepatocellular cancer and acute myeloid leukemia. The drug candidate is a derivative of thienopyridine. It is administered by oral route in the form of pill. It acts by targeting hematopoietic progenitor kinase 1 (HPK1).
Treadwell Therapeutics overview
Treadwell Therapeutics is a clinical-stage biotechnology company that develops novel therapeutics for highly aggressive cancers. The company’s pipeline products include small cell therapeutic products, biologic therapy and T-cell receptor (TCR) based cell therapy products. Its products are used in therapeutic areas that include solid and liquid tumors, breast cancer, prostate cancer, myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), among others. Treadwell Therapeutics leverages deep mechanistic insights and internal discovery tools to uncover novel targets and translate those insights into clinical candidates. The company operates in the US, Canada and Hong Kong. Treadwell Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of CFI-402411’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
